Conference Coverage EHA 2022 – Focus on Multiple Myeloma
The latest therapeutic developments in multiple myeloma – how will they change our approach to treatment patterns?
Faculty Members
Suzanne Lentzsch, MD, PhD
Columbia University, New York, NY, USA
Irene Ghobrial, MD
Dana-Farber Cancer Institute, Boston, MA, USA
María-Victoria Mateos, MD, PhD
University of Salamanca, Spain
Hermann Einsele, MD, FRCP
University Hospital Würzburg, Germany
Mohamad Mohty, MD, PhD
Saint-Antoine Hospital and Sorbonne University, Paris, France
Xavier Leleu, MD, PhD
Poitiers University Hospital, Poitiers, France
REPORT TOPICS
- First Line (1): Smoldering and Transplant-Ineligible Multiple Myeloma
- First Line (2): Induction in Transplant-Eligible Multiple Myeloma
- First Line (3): Maintenance and MRD
- Relapsed/Refractory Multiple Myeloma: First and Second Relapse
- Relapsed/Refractory Multiple Myeloma: Novel Agents
- Relapsed/Refractory Multiple Myeloma: Antibodies and Bispecifics
- Relapsed/Refractory Multiple Myeloma: CAR Ts
